Aβ 42 , Aβ 40 and P-/T-tau levels were assessed locally at the three above named clinical sites levels were defined as >450 pg/ml for T-tau, >61 pg/ml for P-tau and <450 pg/ml for Aβ 42 in 1 study groups A & B and >300 pg/ml for T-tau and <550 pg/ml for Aβ 42 in study group C. The 2 pathological range for the Aβ 42/ Aβ 40 ratio was defined as <0.5 ((Aβ 42 /Aβ 40 ) x 10). APOE 3 genotypes (gene map locus 19q13) were determined also locally at the above named 4 centers via polymerase chain reaction (PCR).
6
KLK8 measurement in CSF and blood 7 All KLK8 measurements were performed in the central reference laboratory at the Institute of 8 Neuropathology, University of Duisburg-Essen. Analyses were performed by an experienced 9 technician who was blinded to participants' diagnoses. KLK8 levels were measured in 10 duplicate using a commercially obtained ELISA kit (#EK0819, Boster Biological Technology,
11
Pleasanton, California, USA) following the manufacturer's instructions. For the entire 12 measurements two different lots of ELISA kits were used; different diagnostic groups were 13 distributed equally between assay lots. Serum samples were diluted in sample buffer (1:2 14 dilution), whereas CSF samples remained undiluted. Agreement between the two 15 measurements was assessed graphically using Bland-Altman plots and scatter plots 16 (supplementary figure 1). Only very few subjects had mean KLK8 values that were outside 17 the 95% confidence interval, implicating a high reliability of KLK8 measurement.
18
We used a commercially available ELISA assay for KLK8 measurements, which hopefully 19 will facilitate reproducibility of our results. The technical specifications of the utilized KLK8 20 ELISA kit are as follows: A) detection limit/sensitivity: <10 pg/ml, B) assay range: 156-10,000 
